Overview

Fibrinolysis Before Cardiopulmonary Bypass?

Status:
Completed

Trial end date:
2014-02-01

Target enrollment:

Participant gender:

Summary

It is common practice to use antifibrinolytic agents before and during cardiopulmonary bypass. They are not without side effects. The investigators want to show that there is no proof of fibrinolysis in standard sternotomy cardiac surgery patients before cardiopulmonary bypass, and that antifibrinolytic agents should only be started on cardiopulmonary bypass.

Phase:

Phase 4

Details

Lead Sponsor:

Stanford University

Treatments:

Aminocaproic Acid
Antifibrinolytic Agents